Welcome to our dedicated page for Grifols S A SEC filings (Ticker: GRFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating donor-center counts, FDA inspection updates, or immunoglobulin margin trends in a 300-page bioscience filing can feel overwhelming. Grifols’ disclosures are packed with plasma-collection metrics, hospital-product data, and complex clinical trial notes—exactly the information analysts need yet struggle to extract.
Stock Titan solves this problem. Our AI reads every Grifols annual report 10-K simplified, Grifols quarterly earnings report 10-Q filing, and Grifols 8-K material events explained the moment they hit EDGAR. It translates bioscience jargon into clear takeaways: how new immunoglobulin batches affect revenue, which diagnostic tests gained regulatory clearance, and where R&D spending is headed. Real-time alerts flag Grifols Form 4 insider transactions real-time, letting you track Grifols executive stock transactions Form 4 before the market digests them.
Want to know why donor-compensation costs moved last quarter? Need the latest segment sales breakout without combing through footnotes? Our platform offers:
- AI-powered summaries for every filing—Grifols SEC filings explained simply
- Instant search across 10-K, 10-Q, 8-K, 13D/G, and Grifols proxy statement executive compensation
- Custom dashboards for Grifols earnings report filing analysis and plasma-center KPIs
- Automatic alerts for Grifols insider trading Form 4 transactions
Save hours decoding regulatory language and focus on decisions, not document hunting. With Stock Titan, understanding Grifols SEC documents with AI becomes straightforward—so you can act on insights while others are still scrolling.
Grifols’ H1-25 results show solid operating momentum and meaningful deleveraging. Revenue rose 7.0% cc to EUR 3.68 bn, fueled by Biopharma +8.2% cc with IG volumes up 12.5% and SCIG +66%. Adjusted EBITDA climbed 12.7% cc to EUR 876 m, lifting margin 80 bps to 23.8% despite IRA headwinds. Net profit jumped nearly 4-fold to EUR 177 m, aided by lower restructuring costs and improved finance charges.
Free cash flow pre-M&A improved EUR 182 m YoY to -14 m (EUR 30 m positive in Q2); leverage fell to 4.2× (5.5× a year earlier) with liquidity of EUR 1.4 bn. The company reinstated a EUR 0.15/share dividend, finalized Biotest delisting to reach 80.3% ownership (EUR 108 m outlay), and reiterated FY-25 guidance while raising FCF pre-M&A outlook to EUR 375-425 m. Pipeline execution remains on track, targeting EU launch of fibrinogen in Q4-25 and US launch H1-26.
Management warns that a weaker USD will pressure reported H2 revenue & EBITDA, but expects neutral impact on profit, leverage and FCF through cost levers. Segment detail: Diagnostic +2.8% cc, BioSupplies -31.8% cc. Albumin declined 3.7% cc YTD but returned to growth in Q2. Overall, the Value Creation Plan is delivering margin gains, cash-flow recovery and balance-sheet repair, though free cash flow and net debt (EUR 9.1 bn) remain key watch points.
Grifols (GRFS) has declared an interim cash dividend of €0.15 per share against FY-2025 earnings. The Board approved the payment on 28 Jul 2025, representing a total cash outlay of €102.1 m after excluding 7.0 m treasury shares. Key timetable:
- Last trading date: 8 Aug 2025
- Ex-dividend: 11 Aug 2025
- Record date: 12 Aug 2025
- Payment date: 13 Aug 2025
FAQ
What is the current stock price of Grifols S A (GRFS)?
What is the market cap of Grifols S A (GRFS)?
